In a new video interview from Brut Media, learn about the therapeutic potential of MDMA-assisted psychotherapy from the perspectives of Dr. Emily Williams, a psychiatrist and MAPS-sponsored researcher, and Army SGT(R) Jon Lubecky, who shares his experience in a clinical trial.

(This article was originally published in the Spring 2017 Edition of the MAPS Bulletin)

In November 2016, the U.S. Food and Drug Administration (FDA) green-lit Phase 3 clinical trials proposed by MAPS to further investigate MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD). This means we are closer than ever before to the reclassification of MDMA for legal clinical use as a prescribed medication.